Skip to main content
      Rheum Now Rheumatology Round-Up — LIVE
      Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheu

      Dr. John Cush RheumNow

      1 week ago
      Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25. 📡 Live https://t.co/GXxmtoluBc
      The DIPSA study: can diet improve PsA?

      Finally a RCT, and the general message is Loose weight, regardless of the diet!

      Aurelie Najm AurelieRheumo

      1 week ago
      The DIPSA study: can diet improve PsA? Finally a RCT, and the general message is Loose weight, regardless of the diet! 3 arms: -Mediterranean diet 31pts -Low-calorie Dietary Approaches (DASH-LC) 30pts -Standard of care 31pts Primary outcome change in DAPSA wk 12 DASH-LC https://t.co/XH9Xdn0g96
      In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under a

      Antoni Chan MD (Prof) synovialjoints

      1 week ago
      In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf
      Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chan

      Richard Conway RichardPAConway

      1 week ago
      Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7
      Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria

      ♥️Criteria score >/= 11pts
      🔸SN 77.8

      sheila RHEUMarampa

      1 week ago
      Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria ♥️Criteria score >/= 11pts 🔸SN 77.8%; SP 95.9% 🔸OR 82.6 Huge endeavor towards standardization of SHI to help improve patient outcomes in the future 👏👏 #ACR25 @RheumNow https://t.co/QrgYlksjZB
      Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo.

      ΔESSDAI at 48wk:

      Jiha Lee JihaRheum

      1 week ago
      Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo. ΔESSDAI at 48wk: Ianalumab QM > PBO, statistically significant But ΔESSDAI ≈ 0.5–1 pt (vs PBO) below MCII (≥ 3) Promising biology, modest clinical gain #ACR25 @RheumNow LB24 https://t.co/8y580ch9iJ
      Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy?

      I

      David Liew drdavidliew

      1 week ago
      Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy? Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2 Very decent on primary (ESSDAI) & we will see this Salivary flow only improved when some at baseline #ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh
      #ACR25 Abstr#LB24 The first Phase 3 RCTs in #Sjogren meeting primary endpoint! In moderate-to-severe activity, both RCTs

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week ago
      #ACR25 Abstr#LB24 The first Phase 3 RCTs in #Sjogren meeting primary endpoint! In moderate-to-severe activity, both RCTs = improvement in ESSDAI vs PBO (pooled effect -1.2 reduction). High PBO rate. PGA, PaGA & Stimulated Salivary Flow) improved. No diff in ESSPRI/FACIT @RheumNow https://t.co/rAs6NeXDIn
      Use of AI in AxSpA imaging for diagnosis. ASembleNet, a hybrid deep learning model, achieved 99% accuracy on coronal and

      Antoni Chan MD (Prof) synovialjoints

      1 week ago
      Use of AI in AxSpA imaging for diagnosis. ASembleNet, a hybrid deep learning model, achieved 99% accuracy on coronal and 98.1% on axial MRI for AS classification, outcomes higher than ResNet50, Xception, and InceptionV3. Validated on ASAS cases, with Grad-CAM interpretability and https://t.co/yU8shaIdP2
      Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI.

      Richard Conway RichardPAConway

      1 week ago
      Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI. Big placebo effect also. Patient and physician global also improved. @RheumNow #ACR25 Abstr#LB24 https://t.co/klhxXW4Jfh
      Fighting fire with butyrate 🔥🚒
      ♦️probiotics and prebiotics

      Dr. Nisha Manek on inflammation and butyrate - it

      sheila RHEUMarampa

      1 week ago
      Fighting fire with butyrate 🔥🚒 ♦️probiotics and prebiotics Dr. Nisha Manek on inflammation and butyrate - it reduces gut inflamm thru the NFKB pathway #ACR25 @RheumNow https://t.co/19XTrKn1iN
      Autologous CAR-Treg in RA, without any lymphodepletion preRx

      Early data from ph1, single dose
      Good initial response, st

      David Liew drdavidliew

      1 week ago
      Autologous CAR-Treg in RA, without any lymphodepletion preRx Early data from ph1, single dose Good initial response, stopped RA Rx, but some rebound Clearly work ongoing but excitement re: - CAR-Treg - RA as target dx - no lymphodepletion @minnakohlermd #ACR25 LB23 @RheumNow https://t.co/azmlFNU02R
      REGULATE RA SBT-77-701
      Engineered Treg cell in Refractory RA population
      6patients

      Safety and tolerability: No DLT, CRS

      Aurelie Najm AurelieRheumo

      1 week ago
      REGULATE RA SBT-77-701 Engineered Treg cell in Refractory RA population 6patients Safety and tolerability: No DLT, CRS or ICANS Efficacy Reduction >50% in TJC and SJC 67% reduction of DAS-CRP >=2 stained up to wk 24 Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0
      Kohler et al. Phase 1 study autologous CAR-Tregs in refractory RA. No lymphodepletion needed! 6 participants. 2 doses, s

      Richard Conway RichardPAConway

      1 week ago

      Kohler et al. Phase 1 study autologous CAR-Tregs in refractory RA. No lymphodepletion needed! 6 participants. 2 doses, second cohort with higher dose better and more sustained response. No CRS or other toxicities. @RheumNow #ACR25 Abstr#LB023 https://t.co/nWva2R7WOQ

      ×